Remember CETP? It was a hot topic in cholesterol-lowering drug development a few years ago, but when Merck & Co finally pulled the plug on anacetrapib five years ago on lacklustre phase 3 data ...

Familial hypercholesterolemia results from gene mutations approximately halving the number of functional LDL receptors in heterozygotes and a greater lack in homozygotes. Reduced receptor-mediated ...